Supporting drug development for COVID-19

April 8, 2020

In this challenging time, we need collaboration and innovation to address complex problems like the COVID-19 pandemic. At Certara, our global team is working with our partners to accelerate bringing scientifically-proven drugs to the patients who need them most.

Spotlight

Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

OTHER VIDEOS

Digital Health solutions for patient centric clinical trials

video | August 24, 2021

Digital health solutions for remote patient data collection and continuous patient monitoring are enabling us to reduce patient burden and accelerate our clinical trials. Halsey Lea, Director Data Science, Data Science & AI, R&D, explains the transformative role that digital connected devices are playing in our smart clinical trial programmes....

Watch Now

EMBL researchers identifying how potential drugs work in the fight against COVID-19

video | April 16, 2020

EMBL researchers are studying how drugs that have shown good results against COVID-19 work in living cells. This will help them to quickly identify other drugs that could treat the disease, which are urgently needed until a vaccine is developed, and possibly afterwards as well....

Watch Now

Why the War on Drugs is a War on People

video | April 14, 2020

The War on Drugs was launched in the United States by former President Richard Nixon in 1971. This allowed for the criminalization of drug use, which led to the mass incarceration of millions of Americans, particularly for communities of color....

Watch Now

Hydroxychloroquine's false hope: How an obscure drug became a coronavirus cure

video | April 13, 2020

Claims about hydroxychloroquine and chloroquine have taken hold of the global consciousness. Online conversations, media articles and politicians’ statements quickly - and incorrectly - labeled it as a ‘cure’ for covid-19, the disease caused by the novel coronavirus....

Watch Now

Spotlight

Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

Events